FDA.reportPublic FDA data

NEVIRAPINE

Substance profile for UNII 99DK7FVK1H, enriched with FDA NDC listings, DailyMed labels, legacy aliases, and open chemistry identifiers.

Chemical structure for NEVIRAPINE
Structure render from PubChem CID 4463

Substance Identity#

UNII
99DK7FVK1H
Preferred term
NEVIRAPINE
Registry number
129618-40-2
Ingredient type
INGREDIENT SUBSTANCE
Molecular formula
C15H14N4O
Chemical structure for NEVIRAPINE
Structure render from PubChem CID 4463

Chemical And Database Identifiers#

InChIKey
NQDJXKOVJZTUJA-UHFFFAOYSA-N
SMILES
CC1=C2NC(=O)C3=CC=CN=C3N(C4CC4)C2=NC=C1
RxCUI
53654
PubChem
4463
NCIt
C29277
INN ID
6815

Open Chemistry Sources#

Source, Identifier, Link table
SourceIdentifierLink
PubChem Compound4463pubchem.ncbi.nlm.nih.gov/compound/4463
PubChem InChIKey SearchNQDJXKOVJZTUJA-UHFFFAOYSA-Npubchem.ncbi.nlm.nih.gov/#query=NQDJXKOVJZTUJA-UHFFFAOYSA-N
RxNorm53654mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=53654
NCI ThesaurusC29277ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29277
FDA Substance Registration System99DK7FVK1Hprecision.fda.gov/uniisearch/srs/unii/99DK7FVK1H

DailyMed Socrata Ingredients#

Type, DailyMed label, SPL version table
TypeDailyMed labelSPL version
ACTIVE MOIETYThese highlights do not include all the information needed to use nevirapine tablets, USP safely and effectively. See full prescribing information for nevirapine tablets, USP. Nevirapine tablets, USP 200 mg, for oral use Initial U.S. Approval: 19961
ACTIVE INGREDIENTThese highlights do not include all the information needed to use nevirapine tablets, USP safely and effectively. See full prescribing information for nevirapine tablets, USP. Nevirapine tablets, USP 200 mg, for oral use Initial U.S. Approval: 19961
ACTIVE INGREDIENTThese highlights do not include all the information needed to use nevirapine tablets safely and effectively. See full prescribing information for nevirapine tablets. Nevirapine Tablets USP, 200 mg Initial U.S. Approval: 19961
ACTIVE MOIETYThese highlights do not include all the information needed to use nevirapine tablets safely and effectively. See full prescribing information for nevirapine tablets. Nevirapine Tablets USP, 200 mg Initial U.S. Approval: 19961
ACTIVE INGREDIENTThese highlights do not include all the information needed to use VIRAMUNE XR safely and effectively. See full prescribing information for VIRAMUNE XR. Viramune XR® (nevirapine) Extended-Release Tablets, for oral use Initial U.S. Approval: 19961
ACTIVE MOIETYThese highlights do not include all the information needed to use VIRAMUNE XR safely and effectively. See full prescribing information for VIRAMUNE XR. Viramune XR® (nevirapine) Extended-Release Tablets, for oral use Initial U.S. Approval: 19961
ACTIVE INGREDIENTThese highlights do not include all the information needed to use VIRAMUNE safely and effectively. See full prescribing information for VIRAMUNE. Viramune® (nevirapine) tablets 200 mg Viramune® (nevirapine) oral suspension 50 mg/5 mL Initial U.S. Approval: 19961
ACTIVE MOIETYThese highlights do not include all the information needed to use VIRAMUNE safely and effectively. See full prescribing information for VIRAMUNE. Viramune® (nevirapine) tablets 200 mg Viramune® (nevirapine) oral suspension 50 mg/5 mL Initial U.S. Approval: 19961
ACTIVE MOIETYNEVIRAPINE TABLET, EXTENDED RELEASE [SANDOZ INC]13
ACTIVE INGREDIENTNEVIRAPINE TABLET, EXTENDED RELEASE [SANDOZ INC]13
ACTIVE INGREDIENTVIRAMUNE (NEVIRAPINE) SUSPENSION VIRAMUNE (NEVIRAPINE) TABLET [BOEHRINGER INGELHEIM PHARMACEUTICALS INC.]13
ACTIVE MOIETYVIRAMUNE (NEVIRAPINE) SUSPENSION VIRAMUNE (NEVIRAPINE) TABLET [BOEHRINGER INGELHEIM PHARMACEUTICALS INC.]13
ACTIVE INGREDIENTVIRAMUNE (NEVIRAPINE) TABLET, EXTENDED RELEASE [BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.]9
ACTIVE MOIETYVIRAMUNE (NEVIRAPINE) TABLET, EXTENDED RELEASE [BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.]9
ACTIVE INGREDIENTNEVIRAPINE TABLET [CAMBER PHARMACEUTICALS, INC.]8
ACTIVE MOIETYNEVIRAPINE TABLET [CAMBER PHARMACEUTICALS, INC.]8
ACTIVE INGREDIENTNEVIRAPINE EXTENDED RELEASE (NEVIRAPINE) TABLET [ALVOGEN INC. ]7
ACTIVE MOIETYNEVIRAPINE EXTENDED RELEASE (NEVIRAPINE) TABLET [ALVOGEN INC. ]7
ACTIVE INGREDIENTNEVIRAPINE TABLET [BRECKENRIDGE PHARMACEUTICAL, INC.]6
ACTIVE MOIETYNEVIRAPINE TABLET [BRECKENRIDGE PHARMACEUTICAL, INC.]6
ACTIVE INGREDIENTNEVIRAPINE TABLET [ALVOGEN INC. ]5
ACTIVE MOIETYNEVIRAPINE TABLET [ALVOGEN INC. ]5
ACTIVE MOIETYNEVIRAPINE SUSPENSION [AUROBINDO PHARMA LIMITED]4
ACTIVE INGREDIENTNEVIRAPINE TABLET [AMNEAL PHARMACEUTICALS OF NEW YORK, LLC]4
ACTIVE MOIETYNEVIRAPINE TABLET [AMNEAL PHARMACEUTICALS OF NEW YORK, LLC]4
ACTIVE INGREDIENTNEVIRAPINE TABLET [APOTEX CORP]4
ACTIVE MOIETYNEVIRAPINE TABLET [APOTEX CORP]4
ACTIVE INGREDIENTNEVIRAPINE TABLET [AUROBINDO PHARMA LIMITED]4
ACTIVE MOIETYNEVIRAPINE TABLET [AUROBINDO PHARMA LIMITED]4
ACTIVE MOIETYNEVIRAPINE TABLET [MYLAN PHARMACEUTICALS INC.]4
ACTIVE INGREDIENTNEVIRAPINE TABLET [MYLAN PHARMACEUTICALS INC.]4
ACTIVE INGREDIENTNEVIRAPINE TABLET [GOLDEN STATE MEDICAL SUPPLY, INC.]3
ACTIVE MOIETYNEVIRAPINE TABLET [GOLDEN STATE MEDICAL SUPPLY, INC.]3
ACTIVE MOIETYNEVIRAPINE TABLET, EXTENDED RELEASE [MYLAN PHARMACEUTICALS INC.]3
ACTIVE INGREDIENTNEVIRAPINE TABLET, EXTENDED RELEASE [MYLAN PHARMACEUTICALS INC.]3
ACTIVE MOIETYNEVIRAPINE SUSPENSION NEVIRAPINE TABLET [ROXANE LABORATORIES, INC.]2
ACTIVE INGREDIENTNEVIRAPINE SUSPENSION NEVIRAPINE TABLET [ROXANE LABORATORIES, INC.]2
ACTIVE INGREDIENTNEVIRAPINE TABLET [CIPLA LIMITED]2
ACTIVE MOIETYNEVIRAPINE TABLET [CIPLA LIMITED]2
ACTIVE MOIETYNEVIRAPINE TABLET, EXTENDED RELEASE [APOTEX CORP]2
ACTIVE INGREDIENTNEVIRAPINE TABLET, EXTENDED RELEASE [APOTEX CORP]2
ACTIVE INGREDIENTNEVIRAPINE TABLET [AMNEAL-AGILA, LLC]1
ACTIVE MOIETYNEVIRAPINE TABLET [AMNEAL-AGILA, LLC]1
ACTIVE INGREDIENTNEVIRAPINE TABLET, EXTENDED RELEASE [MYLAN PHARMACEUTICALS INC.]1
ACTIVE MOIETYNEVIRAPINE TABLET, EXTENDED RELEASE [MYLAN PHARMACEUTICALS INC.]1